Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

Objective Dipeptidase-1 (DPEP-1) is a recently discovered leucocyte adhesion receptor for neutrophils and monocytes in the lungs and kidneys and serves as a potential therapeutic target to attenuate inflammation in moderate-to-severe COVID-19. We aimed to evaluate the safety and efficacy of the DPEP...

Full description

Bibliographic Details
Main Authors: Alain Tremblay, Ranjani Somayaji, Arthur Lau, Fatma Eser, Rahmet Guner, David R Luke, Ŏ Fehmi Tabak, Mark Hepokoski, Nancy Gardetto, Steven A Conrad, Sunil D Kumar, Kalyan Ghosh, Stephen M Robbins, Donna L Senger, Daisy Sun, Rachel K S Lim, Jonathan Liu, Ridvan Karaali, Daniel Muruve
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/3/e076142.full

Internet

https://bmjopen.bmj.com/content/14/3/e076142.full

Similar Items